CEO Message

LiberoThera was established in 2018 aiming to contribute to medical care through innovative drug discoveries utilizing the novel membrane protein technologies invented at RIKEN Institute. Based on its unique cell-free membrane protein synthesis and non-canonical amino acid incorporation technologies, LiberoThera is developing novel therapeutic candidates targeting physiologically important membrane proteins, such as GPCRs.


LiberoThera opens up an exciting new frontier in drug discoveries through the development of first-in-class and best-in-class therapeutics for diseases with high unmet medical needs.



President & CEO Toru Kanke, Ph.D.